Foundation for Prader-Willi Blog

De-Risking Treatment Development: Paving the Way for Therapeutic Successes

The Foundation for Prader-Willi Research (FPWR) employs a "de-risking" funding strategy to accelerate the development of new treatments for Prader-Willi syndrome (PWS). We are here to take the risks, fund new ideas, and help build the resources that ...

November 19, 2024 Read More

Topics: Therapeutic Development, Research, SYS

FPWR Announces 2nd Round of 2024 Grants

We are pleased to announce the recipients of our second round of grants for 2024, totaling $1,681,781 in awards, as part of the Foundation for Prader-Willi Research’s (FPWR) ongoing commitment to advancing research in Prader-Willi syndrome (PWS) and ...

November 13, 2024 Read More

Topics: Research, SYS

Blood Clots in PWS: Risk Factors, Signs & Symptoms

Although rare overall, people with PWS have a higher risk for developing dangerous blood clots than the general population. A blood clot is a mass of blood that has changed from its liquid state into a semi-solid or gel-like form.

November 8, 2024 Read More

Topics: Research

How Should I Talk with My Child About Their PWS Diagnosis?

How should I talk with my child about their PWS diagnosis? This is a question many parents ask as their child grows and differences between them and their typical peers may become more apparent. Will discussing the PWS diagnosis empower their child t...

November 7, 2024 Read More

Topics: Research

2024 FPWR PWS/SYS Research Symposium Retrospective

In September, we were honored to host our annual meeting of researchers, physicians, and pharmaceutical companies interested in Prader-Willi or Schaaf-Yang syndromes. This event is consistently invigorating as the leaders in PWS/SYS research not only...

October 30, 2024 Read More

Topics: Research, Learning

PWS Clinical Trials Alert

FPWR maintains the latest clinical trial information so that you can stay abreast of trial opportunities. Some trials require in-person visits while others can be completed remotely. Some trials are testing new drugs while others are intervention (no...

October 4, 2024 Read More

Topics: Research

New Study Highlights the Severe Impact of COVID-19 for Individuals with PWS

As the COVID-19 pandemic continues to evolve, researchers are working hard to understand how the virus affects individuals with Prader-Willi syndrome (PWS). A recent study by FPWR Grant Recipient Dr. James Luccarelli and colleagues from the Massachus...

September 19, 2024 Read More

Topics: Research

FDA Advisory Committee to Review DCCR as Treatment for Hyperphagia in PWS

The FDA has announced its plan to conduct an Advisory Committee Meeting as part of its review of Soleno Therapeutics' DCCR New Drug Application. The FDA convenes Advisory Committees to provide independent expert advice that contributes to the agency'...

September 3, 2024 Read More

Topics: Research

Exploring Type I and II Deletions in Prader-Willi: Cell-Level Insights

70% of cases of Prader-Willi syndrome are associated with a “deletion” of 5,000–6,000 missing base pairs (bp) of DNA on the paternally inherited copy of chromosome 15. What are the biological consequences of the larger 6,000-bp deletion (typically ca...

August 20, 2024 Read More

Topics: Genetics and Imprinting, Research

Foundation for Prader-Willi Blog | Research

Categories

De-Risking Treatment Development: Paving the Way for Therapeutic Successes

FPWR Announces 2nd Round of 2024 Grants

Blood Clots in PWS: Risk Factors, Signs & Symptoms

How Should I Talk with My Child About Their PWS Diagnosis?

2024 FPWR PWS/SYS Research Symposium Retrospective

PWS Clinical Trials Alert

New Study Highlights the Severe Impact of COVID-19 for Individuals with PWS

FDA Advisory Committee to Review DCCR as Treatment for Hyperphagia in PWS

Exploring Type I and II Deletions in Prader-Willi: Cell-Level Insights

About FPWR

Main Menu

Our Mission

Contact Us